Elicio Therapeutics, Inc.

Phase 2 AI-extracted

ELI-002 7P

adjuvant mKRAS-driven pancreatic ductal adenocarcinoma

Resolved

78days ago

Phase 2 readout · Apr 20, 2026

What's at stake Phase 2 trial results for ELI-002 7P in adjuvant mKRAS-driven pancreatic ductal adenocarcinoma are due Apr 20, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 15h ago

“Su rv iv al P ro ba bi li ty ELI-002 7P DFS: ITT Stratified 20-APR-2026DCO 23.8 (9.8, NE)”

Add to calendar Post on X Reddit

Provenance